China
Africa
Explore chapters and articles related to this topic
Postmenopause
Published in Carolyn Torkelson, Catherine Marienau, Beyond Menopause, 2023
Carolyn Torkelson, Catherine Marienau
A challenge for you and your practitioner is that once you are over age 65, it is much more difficult to get insurance to cover estrogen therapy. The low-dose estrogen patch, while ideal, is especially difficult to get covered, so looking at other less expensive options may be necessary. Using a compounding pharmacy can be a good alternative. Although compounding pharmacies do not make estrogen formulations in a patch form, a topical estrogen (E2 and E3) can work well. Finding the right dose for symptom control often is a trial-and-error process. Some integrative practitioners follow blood, saliva, or urine testing to determine the dosage of hormone supplementation.
Mesotherapy: Dutasteride, Minoxidil, Vitamins
Published in Rubina Alves, Ramon Grimalt, Techniques in the Evaluation and Management of Hair Diseases, 2021
David Saceda, Claudia Bernárdez
Nowadays, we can find different options to perform mesotherapy with dutasteride. According to published data, there is no evidence for a defined concentration of the drug being more effective than others. We can find commercialized injectable dutasteride solution in some countries, usually with a concentration of 0.01%. If it is not available, pharmaceutical compounding can be done. However, a higher concentration is recommended (for instance, 0.05%), in order not to lose a proper amount of dutasteride, as non-industrial preparations may degrade easier.
The Prescription Label
Published in Harvey M. Rappaport, Kelly S. Straker, Tracy S. Hunter, Joseph F. Roy, The Guidebook for Patient Counseling, 2020
Harvey M. Rappaport, Kelly S. Straker, Tracy S. Hunter, Joseph F. Roy
This component is particularly important when compounding requires prescribers to communicate explicit directions to the pharmacist on the ingredients to be mixed, the dosage form to be made, and the amounts to be dispensed. The use of prepared pharmaceuticals have all but reduced this component to identifying the number of dosage units to be dispensed. Nevertheless, this number can be useful as an indicator of length of medication therapy.
Prescription of compounded ophthalmic medications – a pharmacy perspective
Published in Clinical and Experimental Optometry, 2021
‘Compounding’ can be defined as the preparation, mixing, assembling, packaging and labelling of a medicinal product based on a prescription order from a licensed practitioner for the individual patient, for a wide variety of indications.3 Compounding includes the following: preparation of medicine dosage forms for both human and animal patientspreparation of medicines or devices in anticipation of prescription medicine orders based on routine, regularly observed prescribing patternsreconstitution or manipulation of commercial products that may require the addition of one or more ingredientspreparation of medicines or devices for the purposes of, or as an incident or, research (clinical or academic), teaching, or chemical analysispreparation of medicines and devices for the premises of a doctor use where permitted by commonwealth and state lawsynthesis of a radiopharmaceutical medicine, for example, radiolabelling of a ligand with a radioisotope.
Bioidentical hormones
Published in Climacteric, 2021
F. Z. Stanczyk, H. Matharu, S. A. Winer
There is a misconception by some people that the FDA would like to eliminate custom-compounding pharmacies; this is not true. The focus of the FDA is on the subset of inappropriate compounding pharmacies that mislead the public. In fact, the FDA believes that traditional compounding pharmacists provide a valuable medical service to patients who have not been able to find a commercial product that meets their individual needs36. Sometimes a product must be made in a compounding pharmacy because the patient has an allergy, sensitivity or another reason for use. However, to assure optimum quality of compounded products, there must be greater federal and state regulation, standardization and oversight of compounding practices. The new guidance issued by the FDA is a step in the right direction.
3D printing in the design of pharmaceutical dosage forms
Published in Pharmaceutical Development and Technology, 2019
E. B. Souto, J. C. Campos, S. C. Filho, M. C. Teixeira, C. Martins-Gomes, A. Zielinska, C. Carbone, A. M. Silva
Further than market access, other questions arise regarding this technology. For instance, how can regulatory agencies regulate personalized-dose printing? Will pharmacies and hospitals ever be able to produce SODFs locally in a small scale? And if so, would this be considered compounding pharmacy or small-scale production? And in who would lie the liability when a drug causes an adverse reaction? The pharmacist who printed it? The company who produced the starting materials? The company who assembled the 3D-printing machine? These are all questions that need to be answered before 3D-printing can truly claim its part as the lead technology in a tailored-dose pharmaceutical world. Other issue with 3D-printing is that it opens the door for a range of possibilities related to counterfeit drug-products and loss of intellectual rights. Most 3D-printing machines require practically no expertise from the operator, and being inexpensive and small-sized, having a personal 3D-printer will become a standard in a matter of time. The problem with this is that 3D-printing technologies allow users to create practically anything they want with their printer, from counterfeit drugs to machine guns. In a near future, downloadable formulations’ designs will be available online, even if illegally, and users will be able to print them at their own risk at home (Alhnan et al. 2016).